Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Proceedings Article
  • Published:

Challenges for the next decade: allogeneic stem cell transplantation in chronic lymphocytic leukemia

Abstract

Although hematopoietic stem cell transplantation (allogeneic SCT (allo-SCT)) is the treatment of choice for many aggressive hematological malignancies, the role of allo-SCT in chronic lymphocytic leukemia (CLL) is still a matter of debate and can be considered one of the more important challenges for the next decade. In the era of novel drugs and humanized antibodies, the long-term outcome of patients has improved, and a critical reappraisal of autologous and allo-SCT in CLL treatment is warranted.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Michallet M, Dreger P, Sutton L, Brand R, Richards S, van Os M et al., EBMT Chronic Leukemia Working Party. Autologous hematopoietic stem cell transplantation in chronic lymphocytic leukemia: results of European intergroup randomized trial comparing autografting versus observation. Blood 2011; 117: 1516–1521.

    Article  CAS  Google Scholar 

  2. Khouri IF, Keating M, Körbling M, Przepiorka D, Anderlini P, O’Brien S et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998; 16: 2817–2824.

    Article  CAS  Google Scholar 

  3. Corradini P, Dodero A, Farina L, Fanin R, Patriarca F, Miceli R et al. Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pretransplant disease status and histotype heavily influence outcome. Leukemia 2007; 21: 2316–2323.

    Article  CAS  Google Scholar 

  4. Escalón MP, Champlin RE, Saliba RM, Acholonu SA, Hosing C, Fayad L et al. Nonmyeloablative allogeneic hematopoietic transplantation: a promising salvage therapy for patients with non-Hodgkin's lymphoma whose disease has failed a prior autologous transplantation. J Clin Oncol 2004; 22: 2419–2423.

    Article  Google Scholar 

  5. Armand P, Kim HT, Ho VT, Cutler CS, Koreth J, Antin JH et al. Allogeneic transplantation with reduced intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome. Biol Blood Marrow Transplant 2008; 14: 418–425.

    Article  CAS  Google Scholar 

  6. Bloor AJ, Thomson K, Chowdhry N, Verfuerth S, Ings SJ, Chakraverty R et al. High response rate to donor lymphocyte infusion after allogeneic stem cell transplantation for indolent non-Hodgkin lymphoma. Biol Blood Marrow Transplant 2008; 14: 50–58.

    Article  Google Scholar 

  7. Khouri IF, McLaughlin P, Saliba RM, Hosing C, Korbling M, Lee MS et al. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood 2008; 111: 5530–5536.

    Article  CAS  Google Scholar 

  8. Vigouroux S, Michallet M, Porcher R, Attal M, Ades L, Bernard M et al. Long-term outcomes after reduced intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC). Haematologica 2007; 9: 627–634.

    Article  Google Scholar 

  9. Rezvani AR, Storer B, Maris M, Sorror ML, Agura E, Maziarz RT et al. Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma. J Clin Oncol 2008; 26: 211–217.

    Article  Google Scholar 

  10. Dreger P, Corradini P, Kimby E, Michallet M, Milligan D, Schetelig J et al. Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. Leukemia 2007; 21: 12–17.

    Article  CAS  Google Scholar 

  11. Michallet M, Sobh M, Milligan D, Morisset S, Niederwieser D, Koza V et al. Chronic Leukemia Working Party of the EBMT. The impact of HLA matching on long-term transplant outcome after allogeneic hematopoietic stem cell transplantation for CLL: a retrospective study from the EBMT registry. Leukemia 2010; 24: 1725–1731.

    Article  CAS  Google Scholar 

  12. Khouri IF, Bassett R, Poindexter N, O’Brien S, Bueso-Ramos CE, Hsu Y et al. Nonmyeloablative allogeneic stem cell transplantation in relapsed/refractory chronic lymphocytic leukemia: long-term follow-up, prognostic factors, and effect of human leukocyte histocompatibility antigen subtype on outcome. Cancer 2011; 117: 4679–4688.

    Article  Google Scholar 

  13. Shea T, Johnson J, Westervelt P, Farag S, McCarty J, Bashey A et al. Reduced-intensity allogeneic transplantation provides high event-free and overall survival in patients with advanced indolent B cell malignancies: CALGB 109901. Biol Blood Marrow Transplant 2011; 17: 1395–1403.

    Article  Google Scholar 

  14. Dreger P, Döhner H, Ritgen M, Böttcher S, Busch R, Dietrich S et al. Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial. Blood 2010; 116: 2438–2447.

    Article  CAS  Google Scholar 

  15. Logan AC, Gao H, Wang C, Sahaf B, Jones CD, Marshall EL et al. High-throughput VDJ sequencing for quantification of minimal residual disease in chronic lymphocytic leukemia and immune reconstitution assessment. Proc Natl Acad Sci USA 2011; 108: 21194–21199.

    Article  CAS  Google Scholar 

  16. Böttcher S, Ritgen M, Dreger P . Allogeneic stem cell transplantation for chronic lymphocytic leukemia: lessons to be learned from minimal residual disease studies. Blood Rev 2011; 25: 91–96.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to P Corradini.

Ethics declarations

Competing interests

PC has received consulting fees from Sanofi, Novartis and lecture fees from Celgene and Genzyme. LF declares no competing interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Corradini, P., Farina, L. Challenges for the next decade: allogeneic stem cell transplantation in chronic lymphocytic leukemia. Leukemia Suppl 1 (Suppl 2), S33–S34 (2012). https://doi.org/10.1038/leusup.2012.19

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leusup.2012.19

Keywords

Search

Quick links